Bringing the fundamentals into focus…
Back to Zenas BioPharma, Inc.
How Zenas BioPharma, Inc. stacks up
ZBIO · against 1,216 other Healthcare companies
Growth
4/ 100
Near the bottom of its peers.
Ranked #1,163 of 1,217 · scores higher than 4% of peers
Bars: peers in each 10-point band of the growth score116 peers with a growth score of 0–9, including ZBIO · Click a bar to see the companies
Why growth scores 4?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and earnings per share growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 99% of peers. Revenue growth: -93.3% vs peer median 6.1%
- The loss per share widened. Earnings per share growth: — vs peer median 9.8%
- 3-year revenue growth is not reported, so it is left out of the score.
Metric by metric
Position: dot = ZBIO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ZBIO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 1,243 reported | -93.3% | 6.1% | 1% | 33% | |
| Earnings per share growthHigher is better · 682 reported | Not reported | 9.7% | — | — | 33% |
| 3-year revenue growthHigher is better · 1,192 reported | Not reported | 5.8% | — | — | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around ZBIO| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 464M USD | 100 | 53 | |
| 3 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 3 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 3 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 1,163 | 24M SEK (≈$2M) | 4 | 14 | |
| 1,163 | 7.8B USD | 4 | 30 | |
| 1,163 | 223M USD | 4 | 34 | |
| 1,163 | 184M USD | 4 | 33 | |
| 1,163 | 1.8B USD | 4 | 23 | |
| 1,175 | 2.2B CNY (≈$308M) | 3 | 18 | |
| 1,175 | 2.3B CNY (≈$322M) | 3 | 10 | |
| 1,175 | 3.4B CNY (≈$469M) | 3 | 42 | |
| 1,175 | 143.9B JPY (≈$978M) | 3 | 26 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score